الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> mGluR >>Mavoglurant (AFQ056)

Mavoglurant (AFQ056)

رقم الكتالوجGC30778

Mavoglurant (AFQ056) (AFQ056) هو مضاد mGluR5 قوي وانتقائي وغير تنافسي ونشط فمويًا ، مع IC50 من 30 نانومتر.

Products are for research use only. Not for human use. We do not sell to patients.

Mavoglurant (AFQ056) التركيب الكيميائي

Cas No.: 543906-09-8

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
354٫00
متوفر
5mg
321٫00
متوفر
10mg
459٫00
متوفر
50mg
1379٫00
متوفر
100mg
1930٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.IC50 value: 30 nMTarget: mGluR5in vitro: Mavoglurant is a selective non-competitive antagonist which showed efficacy in the treatment of L-dopa induced dyskinesias in Parkinson's disease and Fragile X mental retardation in proof of principle studies. Mavoglurant is selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes. [1]In vivo: Mavoglurant shows an improved pharmacokinetic profile in rat and efficacy in the stress-induced hyperthermia test in mice as compared to the prototypic mGluR5 antagonist MPEP.[1]

[1]. Vranesic I, et al. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem. 2014 Nov 1;22(21):5790-5803.

مراجعات

Review for Mavoglurant (AFQ056)

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mavoglurant (AFQ056)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.